X
<

Boston Scientific’s Product Launches Boost Investor Confidence

PART:
1 2 3 4 5 6
Part 3
Boston Scientific’s Product Launches Boost Investor Confidence PART 3 OF 6

Real-World Data: BSX’s Bronchial Thermoplasty Is Effective in the Long Term

Overview

On September 18, 2017, Boston Scientific (BSX) announced the results of its post-approval clinical trial in the United States for the evaluation of BT (Bronchial Thermoplasty) used for the treatment of the patients who suffer from severe asthma. On the day, BSX stock gained around 0.21%.

The iShares Russell 1000 Growth ETF (IWF) rose around 0.13% on September 18, 2017. IWF holds ~0.33% of its total portfolio in BSX.

Real-World Data: BSX’s Bronchial Thermoplasty Is Effective in the Long Term

Interested in BSX? Don't miss the next report.

Receive e-mail alerts for new research on BSX

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

While pharmaceutical companies such as Pfizer (PFE), Merck (MRK), and GlaxoSmithKline (GSK) develop drugs for the treatment of asthma, Boston Scientific’s Alair BT system is the first device-based treatment for severe asthma patients. The treatment system was approved by the FDA in 2010 for adult asthma patients.

Study results

The PAS2 study, which is a post-approval clinical trial, was conducted at 27 sites across the United States and Canada. The recent study results are based on three-year follow-up data of 190 patients that were part of the PAS2 study.

According to the results, “190 patients in the real-world study achieved similar reductions in severe exacerbations, hospitalizations, and emergency room visits when compared to the 190 patients treated with BT in the pivotal randomized, sham-controlled Asthma Intervention Research 2 (AIR2) trial.”

The study results showed that the patients who underwent BT treatment showed the following performance metrics:

  • The number of patients having severe exacerbations decreased from 74% to 40%.
  • The number of hospitalized patients who had at least one symptom of asthma decreased from 15% to 7%.
  • The number of patients who had to visit the emergency room decreased from 27% to 11%.
  • The number of patients using daily oral corticosteroid medications decreased from 19% to 10%.

In June 2017, Boston Scientific had reported a positive trial outcome showing reduced complications in asthma patients that underwent treatment using BSX’s Alair BT system. For further details, please read How Boston Scientific’s Alair System Performed in Trials.

X

Please select a profession that best describes you: